Literature DB >> 30366163

Use and outcomes of subcutaneous implantable cardioverter-defibrillator (ICD) after transvenous ICD extraction: An analysis of current clinical practice and a comparison with transvenous ICD reimplantation.

Stefano Viani1, Federico Migliore2, Gianfranco Tola3, Ennio C L Pisanò4, Antonio Dello Russo5, Giovanni Luzzi6, Paolo Sartori7, Agostino Piro8, Roberto Rordorf9, Giovanni Battista Forleo10, Anna Rago11, Luca Segreti12, Emanuele Bertaglia2, Mauro Biffi13, Mariolina Lovecchio14, Sergio Valsecchi14, Igor Diemberger13, Maria Grazia Bongiorni12.   

Abstract

BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) does not require the insertion of any leads into the cardiovascular system.
OBJECTIVE: The aims of the study were to describe current practice and to measure outcomes associated with S-ICD or standard single-chamber transvenous ICD (TV-ICD) use after TV-ICD explantation.
METHODS: We analyzed all consecutive patients who underwent transvenous extraction of an ICD and subsequent implantation of an S-ICD or a single-chamber TV-ICD at 12 Italian centers from 2011 to 2017.
RESULTS: A total of 229 patients were extracted and subsequently reimplanted with an S-ICD (90; 39%) or a single-chamber TV-ICD (139; 61%). S-ICD implantation increased from 9% in 2011 to 85% in 2017 (P < .001). Patients reimplanted with an S-ICD were younger (53 ± 13 years vs 60 ± 18 years; P = .011) and more frequently had undergone extraction owing to infection (73% vs 52%; P < .001). The rates of complications at follow-up were comparable between groups (hazard ratio 0.97; 95% confidence interval 0.49-1.92; P = .940). No lead failures, systemic infections, or system-related deaths occurred in the S-ICD group. In the TV-ICD group, 1 lead fracture occurred and 2 systemic infections were reported, resulting in death in 1 case. In the S-ICD group, the rate of complications was lower when the generator was positioned in a sub- or intermuscular pocket (hazard ratio 0.21; 95% confidence interval 0.05-0.87; P = .048).
CONCLUSION: Our results show an increasing use of S-ICD over the years in patients undergoing TV-ICD explantation. An S-ICD is preferably adopted in young patients, mostly in the case of infection. The complication rate was comparable between groups and decreased when a sub- or intermuscular S-ICD generator position was adopted.
Copyright © 2018 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ICD complications; Implantable cardioverter-defibrillator; Lead extraction; Subcutaneous implantable cardioverter defibrillator; Sudden cardiac death

Mesh:

Year:  2018        PMID: 30366163     DOI: 10.1016/j.hrthm.2018.10.026

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  8 in total

1.  Prevention of cardiac implantable electronic device infections: guidelines and conventional prophylaxis.

Authors:  Carina Blomstrom-Lundqvist; Bozena Ostrowska
Journal:  Europace       Date:  2021-05-25       Impact factor: 5.214

2.  Transvenous Lead Extraction in Patients with Cardiac Implantable Device: The Impact of Systemic and Local Infection on Clinical Outcomes-An ESC-EHRA ELECTRa (European Lead Extraction Controlled) Registry Substudy.

Authors:  Igor Diemberger; Luca Segreti; Christopher A Rinaldi; Jesper Hastrup Svendsen; Andrzej Kutarski; Arwa Younis; Cécile Laroche; Christophe Leclercq; Barbara Małecka; Przemyslaw Mitkowski; Maria Grazia Bongiorni
Journal:  Biology (Basel)       Date:  2022-04-18

3.  European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Carina Blomström-Lundqvist; Vassil Traykov; Paola Anna Erba; Haran Burri; Jens Cosedis Nielsen; Maria Grazia Bongiorni; Jeanne Poole; Giuseppe Boriani; Roberto Costa; Jean-Claude Deharo; Laurence M Epstein; Laszlo Saghy; Ulrika Snygg-Martin; Christoph Starck; Carlo Tascini; Neil Strathmore
Journal:  Europace       Date:  2020-04-01       Impact factor: 5.214

4.  Two Limitations of Subcutaneous Implantable Cardioverter Defibrillator in the Same Patient Warranting Its Explant.

Authors:  Rahul Dhawan; Mansoor Ahmad; Aravdeep Jhand; Sumera Kanwal; Adeel Jamil; Faris Khan
Journal:  Am J Case Rep       Date:  2021-04-29

Review 5.  Process mapping strategies to prevent subcutaneous implantable cardioverter-defibrillator infections.

Authors:  Raul Weiss; George E Mark; Mikhael F El-Chami; Mauro Biffi; Vincent Probst; Pier D Lambiase; Marc A Miller; Timothy McClernon; Linda K Hansen; Bradley P Knight; Larry M Baddour
Journal:  J Cardiovasc Electrophysiol       Date:  2022-06-09       Impact factor: 2.942

6.  Outcomes in Brugada Syndrome Patients With Implantable Cardioverter-Defibrillators: Insights From the SGLT2 Registry.

Authors:  Sharen Lee; Ka Hou Christien Li; Jiandong Zhou; Keith Sai Kit Leung; Rachel Wing Chuen Lai; Guoliang Li; Tong Liu; Konstantinos P Letsas; Ngai Shing Mok; Qingpeng Zhang; Gary Tse
Journal:  Front Physiol       Date:  2020-03-10       Impact factor: 4.566

7.  Diagnosis and management of subcutaneous implantable cardioverter-defibrillator infections based on process mapping.

Authors:  Larry M Baddour; Raul Weiss; George E Mark; Mikhael F El-Chami; Mauro Biffi; Vincent Probst; Pier D Lambiase; Marc A Miller; Timothy McClernon; Linda K Hansen; Bradley P Knight
Journal:  Pacing Clin Electrophysiol       Date:  2020-04-23       Impact factor: 1.976

Review 8.  State-of-the-art consensus on non-transvenous implantable cardioverter-defibrillator therapy.

Authors:  Christoph Schukro; David Santer; Günther Prenner; Markus Stühlinger; Martin Martinek; Alexander Teubl; Deddo Moertl; Stefan Schwarz; Michael Nürnberg; Lukas Fiedler; Robert Hatala; Cesar Khazen
Journal:  Clin Cardiol       Date:  2020-08-14       Impact factor: 2.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.